Semax: What Patients Need to Know About This Cognitive Peptide

Semax is unusual in the world of compounded peptides: it has genuine human clinical evidence behind it, a drug approval history in another country, and a delivery method that does not require injection. For patients exploring cognitive support and neuroprotection, it deserves a serious look.

What Semax is

Semax is a synthetic analogue of a fragment of ACTH (adrenocorticotropic hormone), specifically designed to enhance and prolong the neurological effects of that fragment without triggering the hormonal effects of full ACTH. It was developed in the 1980s by the Institute of Molecular Genetics at the Russian Academy of Sciences.

In Russia, Semax has been an approved pharmaceutical drug since the 1990s. It is available as a prescription nasal spray in 0.1% and 1% concentrations and is used clinically for stroke recovery, traumatic brain injury, cognitive impairment, optic nerve disease, and ADHD-like presentations. This is not fringe research. Semax has a functioning regulatory history in a major country with clinical use spanning more than 25 years.

How it works

Semax's primary mechanism involves increasing the expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the brain. BDNF is essential for neuroplasticity: it supports the formation of new neural connections, protects existing neurons, and plays a key role in learning and memory consolidation.

Semax also modulates dopamine and serotonin activity in the prefrontal cortex, which may explain the improvements in focus and working memory that are among the most consistently reported effects in both clinical studies and patient experience.

Unlike stimulants, Semax does not work by forcing neurotransmitter release. It works by supporting the brain's own adaptive machinery. This is why the cognitive effects tend to feel less like a switch being flipped and more like a gradual increase in cognitive resilience over several weeks.

What the research shows

Stroke recovery. Russian clinical trials show reduced neurological deficits and improved functional outcomes when Semax is given in the acute and subacute phase after ischemic stroke. This is the indication for which it has the strongest published evidence base.

Cognitive function and ADHD. Clinical observations and small trials document improvements in attention, working memory, and processing speed in patients with ADHD and mild cognitive impairment. The effect profile is more subtle than stimulant medications but is associated with fewer side effects.

Optic nerve disease. Studies in optic nerve atrophy and glaucoma-related vision loss show protective effects, likely through the BDNF mechanism. This is a less common use case but a meaningful one for the relevant patient population.

Neuroprotection broadly. BDNF upregulation supports neuronal survival under conditions of stress, injury, or age-related decline. This is the basis for Semax's use in longevity and cognitive preservation protocols, particularly among adults over 40 who are proactively managing brain health.

Who uses it and why

• Patients recovering from stroke or traumatic brain injury. This is the best-evidenced use case, backed by Russian clinical trial literature. The time-sensitive nature of neuroprotection after acute injury makes early access meaningful for this group.
• Adults with ADHD or executive function challenges. Semax is sometimes used as an adjunct or alternative to stimulant medications, particularly for patients who do not tolerate stimulants well or want to avoid the appetite suppression and cardiovascular effects they carry.
• Professionals and older adults focused on cognitive longevity. The BDNF mechanism makes Semax relevant for anyone looking to support neuroplasticity and protect cognitive function over time. This patient profile is growing as awareness of brain health and cognitive preservation increases.

Delivery: nasal spray vs. injection

Semax is most commonly administered as a nasal spray, which is how it is used clinically in Russia. Nasal delivery allows the peptide to reach the central nervous system more directly than subcutaneous injection, bypassing the blood-brain barrier through the olfactory pathway. For a compound whose primary target is the brain, this is a meaningful pharmacological advantage.

Injectable Semax is also available and used by some practitioners. Some prefer injection for systemic indications, while nasal spray is generally preferred for central nervous system effects. Your provider will guide the choice based on your specific goals and the protocol they recommend.

Side effects reported

Semax is generally well tolerated. The most commonly reported side effects are mild irritability in the first few days, mild headache (more common with nasal spray than injection), and sleep disruption if taken too late in the day. Morning administration is typically recommended to avoid the sleep issue.

Because Semax increases dopamine activity in the prefrontal cortex, some patients notice a slight shift in mood or energy in the first week that normalizes as the brain adapts. This is not a pharmacological dependence mechanism. Semax does not produce the rebound effects associated with stimulant medications.

Semax and the 2026 FDA review

Semax is among the peptides included in the FDA Pharmacy Compounding Advisory Committee review process. A favorable outcome would allow US compounding pharmacies to prepare Semax for patients with valid prescriptions. Given its more extensive human clinical history compared to several of the other peptides under review, it is a meaningful candidate for Category 1 restoration.

PepVitaRx is building waitlist infrastructure so patients interested in Semax have a clear path to early access after FDA clearance.